| We have been involved in a number of steering groups representing patient interests on things like Part IX drug tariffs. | 患者教育
> 患者信息 | 监管合作伙伴关系
> 与监管机构合作 | 10,000 | National | Rarely | 119020374306 |
| Scottish Medicine Committee. | 患者权益倡导
> 药物及相关治疗 | 监管合作伙伴关系
> 与监管机构合作 | 100 | National | Sometimes | 119058695466 |
| At NICE [National Institute for Health and Care Excellence], for new drugs, which are few and far between. | 皮肤
> 脱发 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Sometimes | 119011239403 |
| Patient voice through NICE [National Institute for Health and Care Excellence] process. | 稀有
> 罕见病：遗传性 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | International | Regularly | 119011335182 |
| HTAs [Health Technology Assessments] and system updates and shaping. | 癌症
> 癌症：脑 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119011544745 |
| HTAs [Health Technology Assessments] by NICE [National Institute for Health and Care Excellence], SMC [Scottish Medicines Consortium], and NCPE [National Centre for Pharmacoeconomics] for MPN [Myeloproliferative Neoplasm] drugs. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Regularly | 119012976905 |
| NICE [National Institute for Health and Care Excellence] HST [Highly Specialised Technologies] Approvals. | 稀有
> 罕见病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | International | Rarely | 119016699229 |
| In the UK, we are involved with NICE [National Institute for Health and Care Excellence] around inputting views around these issues. | 稀有
> 罕见病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 119020204012 |
| NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments] for all technologies related to renal cell carcinoma, NICE kidney cancer guidelines, NICE RCC [Renal Cell Carcinoma] quality standards, NICE RCC pathways model. | 癌症
> 癌症：肾脏 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119020208300 |
| We link in with NICE [National Institute for Health and Care Excellence] in the UK to represent patient voice. | 稀有
> 罕见病：神经系统 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Rarely | 119020208461 |
| We are regularly involved in NICE [National Institute for Health and Care Excellence] and SMC [Scottish Medicines Consortium] appraisals. | 神经肌肉
> 肌营养不良症 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Regularly | 119020240119 |
| We have sent statements to NICE [National Institute for Health and Care Excellence] during several new treatments submissions/appraisals. | 癌症
> 癌症：肺 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 119020270255 |
| We contribute to technology appraisals undertaken by the UK regulator NICE [National Institute for Health and Care Excellence]. | 未指定
> 未指定 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 119020347454 |
| Taking part in the NICE [National Institute for Health and Care Excellence] appraisal of drug vorasidenib [targeted oral cancer medication]. | 癌症
> 癌症：脑 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Rarely | 119020588088 |
| TSA [Tuberous Sclerosis Association] works with NICE [National Institute for Health and Care Excellence], SMC [Scottish Medicines Consortium], and AWMSG [All Wales Medicines Strategy Group] to ensure patient voice is at the heart of any decision-making by regulatory bodies. | 稀有
> 结节性硬化症 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Regularly | 119020927474 |
| We accept all invitations to participate in HTAs [Health Technology Assessments] as a stakeholder. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Regularly | 119023725459 |
| NICE [National Institute for Health and Care Excellence]. | 癌症
> 癌症：头颈部 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | International | Regularly | 119035824669 |
| We input to NICE [National Institute for Health and Care Excellence] as a stakeholder. | 神经系统
> 神经纤维瘤病（NF） | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Sometimes | 119035847489 |
| NICE [National Institute for Health and Care Excellence] and NHSE's [National Health Service England's] commissioning bodies. | 癌症
> 癌症：医学研究 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | International | Rarely | 119044184579 |
| Currently supporting a pharma company going through the NICE [National Institute for Health and Care Excellence] process. | 神经退行性
> 运动神经元疾病（MND） | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Rarely | 119044293510 |
| NICE [National Institute for Health and Care Excellence] and Optune - TTF [Tumour Treating Fields]. | 癌症
> 癌症：脑 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 119051192063 |
| To NICE [National Institute for Health and Care Excellence] regarding metreleptin. | 稀有
> 罕见病：其他 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Rarely | 119051196563 |
| NICE [National Institute for Health and Care Excellence] drug appraisals and SMC [Scottish Medicines Consortium], etc. | 癌症
> 癌症：肉瘤 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Regularly | 119051196659 |
| In the UK, the health system is very different. The charity does support reviews by NICE [National Institute for Health and Care Excellence], which decide on whether a new drug is adopted by the National Health Care System (NHS [National Health Service]). | 神经退行性
> 帕金森病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Rarely | 119051328349 |
| We input to NICE [National Institute for Health and Care Excellence] and HTA [Health Technology Assessment] work. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Regularly | 119051367524 |
| We were involved in NICE [National Institute for Health and Care Excellence] scoping and appraisal (and an appeal) of collagenase. | 残疾
> 残疾：其他 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Not specified | National | Rarely | 119051586905 |
| NICE [National Institute for Health and Care Excellence] Technology appraisal committee submissions. | 出血
> 出血性疾病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Regularly | 119059132955 |
| NICE [National Institute for Health and Care Excellence] MTA [Multiple Technology Appraisal] & STA [Single Technology Appraisal] Ultra Orphan. | 神经肌肉
> 脊髓性肌萎缩症（SMA） | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Regularly | 119059238135 |
| Supporting Patient representatives at HTA [Health Technology Assessment]. | 肾脏
> 肾脏疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Over 100,000 | National | Regularly | 119064494675 |
| We respond during the consultation period of NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments]. | 患者权益倡导
> 健康活动人士 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Sometimes | 119072915914 |
| NICE [National Institute for Health and Care Excellence]/SMC [Scottish Medicines Consortium]. | 癌症
> 癌症：其他 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Sometimes | 119073770394 |
| Our organisation will respond to relevant NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments] for new, innovative medicines. We represent the patient voice during such processes. | 患者权益倡导
> 健康活动人士 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Sometimes | 119074520649 |
| We've spoken to NICE [National Institute for Health and Care Excellence]. | 神经系统
> 疼痛 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Rarely | 119075975011 |
| NICE [National Institute for Health and Care Excellence] and MRHA [Medicines and Healthcare products Regulatory Agency]. | 血液
> 血液疾病：其他 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | International | Regularly | 119076415433 |
| We have contributed to NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments]. | 癌症
> 癌症：胆管 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 119076676177 |
| Submission to HTA [Health Technology Assessment]. | 癌症
> 癌症：肺 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | International | Sometimes | 119078029243 |
| We represent our community to NICE [National Institute for Health and Care Excellence] and SMC [Scottish Medicines Consortium]. | 癌症
> 癌症：卵巢癌 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119078342555 |
| NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments] for all technologies related to renal cell carcinoma, NICE kidney cancer guidelines, NICE RCC [Renal Cell Carcinoma] quality standards, NICE RCC pathways model. | 癌症
> 癌症：肾脏 | 监管合作伙伴关系
> 参与临床指南制定机构 | 100,000 | National | Regularly | 119020208300 |
| Representatives participate in NIHR [National Institute for Health Research] & NICE [National Institute for Health and Care Excellence] organised meetings and committees. | 癌症
> 癌症：头颈部 | 监管合作伙伴关系
> 参与临床指南制定机构 | 10,000 | National | Sometimes | 119078408059 |
| We are often part of NICE [National Institute for Health and Care Excellence] recommendations panels as patient advocates. | 癌症
> 癌症：肾脏 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Regularly | 119011231734 |
| The recent NICE approval of Leo Pharma's Delgocitinib. We spoke on behalf of patients (in favour) at the Board Review. | 皮肤
> 特应性皮炎/湿疹 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 5,000 | National | Regularly | 119012180050 |
| In the UK, we are involved with NICE [National Institute for Health and Care Excellence] around inputting views around these issues. | 稀有
> 罕见病：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | National | Sometimes | 119020204012 |
| TSA [Tuberous Sclerosis Association] works with NICE [National Institute for Health and Care Excellence], SMC [Scottish Medicines Consortium], and AWMSG [All Wales Medicines Strategy Group] to ensure patient voice is at the heart of any decision-making by regulatory bodies. | 稀有
> 结节性硬化症 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 5,000 | National | Regularly | 119020927474 |
| Representatives participate in NIHR [National Institute for Health Research] & NICE [National Institute for Health and Care Excellence] organised meetings and committees. | 癌症
> 癌症：头颈部 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Sometimes | 119078408059 |
| Work in conjunction with national and international organisations and charities. | 呼吸系统
> 间质性肺疾病（ILD） | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | Local | Regularly | 119038282972 |
| We are an alliance of patient organizations and alliances. | 患者权益倡导
> 患者权益倡导 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | Over 100,000 | International | Regularly | 119068858860 |
| HTAs [Health Technology Assessments] and system updates and shaping. | 癌症
> 癌症：脑 | 影响政策和立法
> 影响医疗保健政策和立法 | 100,000 | National | Regularly | 119011544745 |
| ... Work with government members of parliament [UK] campaigning for better recognition of pulmonary fibrosis, additional funding for the treatment of the disease, greater support for the patients with the disease along with their families, carers and friends. | 呼吸系统
> 间质性肺疾病（ILD） | 影响政策和立法
> 影响医疗保健政策和立法 | 100 | Local | Regularly | 119038282972 |
| Advocacy for essential medications list, access in low and middle income countries, and working with WHO on global health goals related to obesity care. | 总体健康
> 肥胖症 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | International | Sometimes | 119076572106 |
| We have been involved in a number of steering groups representing patient interests on things like Part IX drug tariffs. | 患者教育
> 患者信息 | 影响政策和立法
> 参与公众听证会和咨询 | 10,000 | National | Rarely | 119020374306 |
| ... Work with government members of parliament campaigning for better recognition of pulmonary fibrosis, additional funding for the treatment of the disease, greater support for the patients with the disease along with their families, carers and friends. | 呼吸系统
> 间质性肺疾病（ILD） | 影响政策和立法
> 动员议员和政治领导人 | 100 | Local | Regularly | 119038282972 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者安全
> 医源性 | 影响政策和立法
> 动员议员和政治领导人 | 5,000 | International | Sometimes | 119051418184 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者安全
> 医源性 | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | International | Sometimes | 119051418184 |
| We have been involved in a number of steering groups representing patient interests on things like Part IX drug tariffs The Drug Tariff is the NHS document that sets out what pharmacies and dispensing contractors are paid for medicines and medical devices. Part IX specifically covers medical appliances and chemical reagents that can be prescribed on the NHS and how they are reimbursed]. | 患者教育
> 患者信息 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 10,000 | National | Rarely | 119020374306 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者安全
> 医源性 | 定价与可负担性倡导
> 跟踪和监控药品定价/药品短缺 | 5,000 | International | Sometimes | 119051418184 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者安全
> 医源性 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | International | Sometimes | 119051418184 |
| Patient advocacy and support for patients and their families or caregivers. | 血液
> 血栓性血小板减少性紫癜（TTP） | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | International | Regularly | 119066129426 |
| Advocacy for essential medications list, access in low and middle income countries. | 总体健康
> 肥胖症 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | International | Sometimes | 119076572106 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者安全
> 医源性 | 改善访问路径
> 解决访问和管理方面的差距 | 5,000 | International | Sometimes | 119051418184 |
| Advocacy for essential medications list, access in low and middle income countries. | 总体健康
> 肥胖症 | 改善访问路径
> 解决访问和管理方面的差距 | 1,000 | International | Sometimes | 119076572106 |
| NICE [National Institute for Health and Care Excellence] MTA [Multiple Technology Appraisal] & STA [Single Technology Appraisal] Ultra Orphan. | 神经肌肉
> 脊髓性肌萎缩症（SMA） | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 5,000 | National | Regularly | 119059238135 |
| Patient voice through NICE [National Institute for Health and Care Excellence] process. | 稀有
> 罕见病：遗传性 | 循证患者意见
> 利用患者洞察来指导决策 | 5,000 | International | Regularly | 119011335182 |
| We are regularly involved in NICE [National Institute for Health and Care Excellence] and SMC [Scottish Medicines Consortium] appraisals. We ensure patients' experience and voices are heard throughout the appraisal and highlight the impact a new treatment has. | 神经肌肉
> 肌营养不良症 | 循证患者意见
> 利用患者洞察来指导决策 | 10,000 | National | Regularly | 119020240119 |
| Taking part in the NICE [National Institute for Health and Care Excellence] appraisal of drug vorasidenib [oral cancer therapy for people with gliomas]. | 癌症
> 癌症：脑 | 循证患者意见
> 利用患者洞察来指导决策 | 1,000 | National | Rarely | 119020588088 |
| We link in with NICE [National Institute for Health and Care Excellence] in the UK to represent patient voice. | 稀有
> 罕见病：神经系统 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 1,000 | National | Rarely | 119020208461 |
| We are often part of NICE [National Institute for Health and Care Excellence] recommendations panels as patient advocates. | 癌症
> 癌症：肾脏 | 机构治理
> 确保在政府咨询机构中的代表性 | 10,000 | National | Regularly | 119011231734 |
| Often involved in government focus groups in a patient advocacy role. | 神经系统
> 疼痛 | 机构治理
> 确保在政府咨询机构中的代表性 | 5,000 | National | Rarely | 119014421396 |
| We represent our community to NICE [National Institute for Health and Care Excellence] and SMC [Scottish Medicines Consortium]. | 癌症
> 癌症：卵巢癌 | 机构治理
> 确保在政府咨询机构中的代表性 | 100,000 | National | Regularly | 119078342555 |
| UKTS [United Kingdom Thalassaemia Society] are part of Prescription charges coalition. | 血液
> 地中海贫血 | 机构治理
> 在多利益相关方网络中高效协作 | 5,000 | National | Sometimes | 119069553871 |
| Social inclusion. | 患者权益倡导
> 患者权益倡导 | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 100 | National | Sometimes | 119045177344 |
互动
行动与倡导
46 提及
